Patient-Friendly Explanation
Weight-loss medications are usually paid for out of pocket, so the monthly cost directly affects how regularly someone can take them. When money is tight, patients often cut doses, stretch out their supply or stop without telling anyone, and the results are worse for it. Asking early about subsidies, cheaper equivalents and payment options usually keeps treatment on track.
Clinical Definition
Out-of-pocket cost is among the strongest modifiable predictors of non-persistence with anti-obesity pharmacotherapy, and discontinuation is typically followed by weight regain within months. Cost-related non-adherence takes the form of skipped doses, extended dosing intervals and interrupted supply, all of which hold drug exposure below effective levels and can also provoke reintroduction side effects when treatment restarts.
Why It Matters
Cost has to be planned from the first consultation: total duration, whether a generic or biosimilar equivalent exists, and what will happen to weight if treatment stops. An agreed and monitored stopping point is clinically far cheaper than an unplanned one, and the conversation also prevents silent dose-cutting.